110 related articles for article (PubMed ID: 32266820)
1. The expression of CD73 on pathological B-cells is associated with shorter overall survival of patients with CLL.
Kicova M; Michalova Z; Coma M; Gabzdilova J; Dedinska K; Guman T; Bernatova S; Hajikova M; Giertlova M; Veselinyova D; Sarissky M
Neoplasma; 2020 Jul; 67(4):933-938. PubMed ID: 32266820
[TBL] [Abstract][Full Text] [Related]
2. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
[TBL] [Abstract][Full Text] [Related]
3. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
4. Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis.
Botta Gordon-Smith S; Ursu S; Eaton S; Moncrieffe H; Wedderburn LR
Arthritis Rheumatol; 2015 Feb; 67(2):545-54. PubMed ID: 25418634
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
6. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
[TBL] [Abstract][Full Text] [Related]
7. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
[TBL] [Abstract][Full Text] [Related]
8. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
9. Profound inhibition of CD73-dependent formation of anti-inflammatory adenosine in B cells of SLE patients.
Hesse J; Siekierka-Harreis M; Steckel B; Alter C; Schallehn M; Honke N; Schnieringer ML; Wippich M; Braband R; Schneider M; Surowy H; Wieczorek D; Schrader J; Pongratz G
EBioMedicine; 2021 Nov; 73():103616. PubMed ID: 34666225
[TBL] [Abstract][Full Text] [Related]
10. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
11. Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway.
Yu J; Wang X; Lu Q; Wang J; Li L; Liao X; Zhu W; Lv L; Zhi X; Yu J; Jin Y; Zou Q; Ou Z; Liu X; Zhou P
Int J Cancer; 2018 Mar; 142(5):959-967. PubMed ID: 29047106
[TBL] [Abstract][Full Text] [Related]
12. Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.
Yang J; Liao X; Yu J; Zhou P
Curr Med Chem; 2018; 25(19):2260-2271. PubMed ID: 29345574
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
Morello S; Capone M; Sorrentino C; Giannarelli D; Madonna G; Mallardo D; Grimaldi AM; Pinto A; Ascierto PA
J Transl Med; 2017 Dec; 15(1):244. PubMed ID: 29202855
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.
Jiang T; Xu X; Qiao M; Li X; Zhao C; Zhou F; Gao G; Wu F; Chen X; Su C; Ren S; Zhai C; Zhou C
BMC Cancer; 2018 Mar; 18(1):267. PubMed ID: 29514610
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics and clinical significance of CD73 expression in subtypes of leukemia].
Zhao SX; Zhang HM; Dong SX; Liu JH; Zhou Z; Wang HJ; Zhu XF; Mi YC; Ru YX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1141-4. PubMed ID: 22040959
[TBL] [Abstract][Full Text] [Related]
16. Enzyme activity of circulating CD73 in human serum.
Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
[TBL] [Abstract][Full Text] [Related]
17. CD73 is associated with poor prognosis in HNSCC.
Ren ZH; Lin CZ; Cao W; Yang R; Lu W; Liu ZQ; Chen YM; Yang X; Tian Z; Wang LZ; Li J; Wang X; Chen WT; Ji T; Zhang CP
Oncotarget; 2016 Sep; 7(38):61690-61702. PubMed ID: 27557512
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance.
Jain D; Somasundaram DB; Aravindan S; Yu Z; Baker A; Esmaeili A; Aravindan N
Cell Biol Toxicol; 2023 Jun; 39(3):967-989. PubMed ID: 34773529
[TBL] [Abstract][Full Text] [Related]
19. The first CD73-instructed supramolecular hydrogel.
Wu D; Du X; Shi J; Zhou J; Zhou N; Xu B
J Colloid Interface Sci; 2015 Jun; 447():269-72. PubMed ID: 25524006
[TBL] [Abstract][Full Text] [Related]
20. CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
Leclerc BG; Charlebois R; Chouinard G; Allard B; Pommey S; Saad F; Stagg J
Clin Cancer Res; 2016 Jan; 22(1):158-66. PubMed ID: 26253870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
